These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 7388548)
21. [Platelet antiaggregants and arteriopathies]. Cristol R J Mal Vasc; 1981; 6(3):237-41. PubMed ID: 7026714 [No Abstract] [Full Text] [Related]
22. Antiplatelet drugs in the secondary prevention of myocardial infarction. One view of the present position. McNicol GP Lancet; 1980 Oct; 2(8197):736-8. PubMed ID: 6106840 [No Abstract] [Full Text] [Related]
23. [Treatment and prevention of thromboembolism with anti-aggregation drugs]. Donner L Vnitr Lek; 1981 May; 27(5):487-95. PubMed ID: 7245635 [No Abstract] [Full Text] [Related]
24. Secondary prevention of myocardial infarction. Davies JA Int J Clin Pharmacol Res; 1985; 5(5):303-7. PubMed ID: 3905632 [TBL] [Abstract][Full Text] [Related]
25. [Treatment of myocardial infarct with anticoagulants, thrombolytics, inhibitors of platelet aggregation and beta receptor blockaders]. Thiele R Z Arztl Fortbild (Jena); 1984; 78(5):167-71. PubMed ID: 6202068 [No Abstract] [Full Text] [Related]
27. [Thrombosis prevention with thrombocyte aggregation inhibitors in the venous system]. Schöndorf TH Med Welt; 1982 Jun; 33(23):851-4. PubMed ID: 7050615 [No Abstract] [Full Text] [Related]
28. Use of platelet antagonists in the treatment of migraine. Dalessio DJ Headache; 1976 Jul; 16(3):129-30. PubMed ID: 965226 [No Abstract] [Full Text] [Related]
29. 10. Antithrombotic therapy: role of platelet-inhibitor drugs. II. Pharmacologic effects of platelet-inhibitor drugs (second of three parts). Fuster V; Chesebro JH Mayo Clin Proc; 1981 Mar; 56(3):185-95. PubMed ID: 7010003 [TBL] [Abstract][Full Text] [Related]
30. Secondary prevention of myocardial infarction--the present state of the ART. Mitchell JR Br Med J; 1980 May; 280(6223):1128-30. PubMed ID: 7000236 [No Abstract] [Full Text] [Related]
31. Prophylaxis of myocardial infarction. de Bono DP Scott Med J; 1981 Jul; 26(3):194-6. PubMed ID: 6115470 [No Abstract] [Full Text] [Related]
34. Antiplatelet drugs or dicoumarol: what is the most effective prophylaxis in occlusive arterial disease? Poliwoda H; Avenarius HJ Int Angiol; 1986; 5(3):169-80. PubMed ID: 2435823 [TBL] [Abstract][Full Text] [Related]
35. Platelet function inhibitors: their clinical use. Fuster V; Didisheim P Adv Intern Med; 1978; 23():251-64. PubMed ID: 343540 [No Abstract] [Full Text] [Related]
36. [Prevention of cardiovascular diseases by inhibitors of platelet aggregation (author's transl)]. Boeynaems JM Rev Med Brux; 1982 Jun; 3(6):415-24. PubMed ID: 7111939 [No Abstract] [Full Text] [Related]
37. Antiplatelet agents in prevention of myocardial infarction. Kshirsagar NA Indian Heart J; 1983; 35(1):60-6. PubMed ID: 6303947 [No Abstract] [Full Text] [Related]
38. [Therapy with anticoagulants and platelet aggregation inhibitors in extracranial vascular stenoses and occlusions]. Ostendorf P Internist (Berl); 1979 Nov; 20(11):539-46. PubMed ID: 396265 [No Abstract] [Full Text] [Related]
39. Role of blood platelets in coronary artery disease. Haft JI Am J Cardiol; 1979 Jun; 43(6):1197-206. PubMed ID: 35967 [TBL] [Abstract][Full Text] [Related]
40. [Results of clinical studies on the effect of aggregation inhibitors in arterial diseases]. Loew D Med Welt; 1979 Feb; 30(5):166-9. PubMed ID: 759804 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]